Prevaccination Rotavirus Serum IgG and IgA Are Associated with Lower Immunogenicity of Live, Oral Human Rotavirus Vaccine in South African Infants

Clinical Infectious Diseases

Volumn 62, Issue 2, 2016, Pages 157-165

  Moon, Sung Sil ^a   Groome, Michelle J ^b,c   Velasquez, Daniel E ^a   Parashar, Umesh D ^a   Jones, Stephanie ^b,c   Koen, Antoinette ^b,c   Van Niekerk, Nadia ^b,c   Jiang, Baoming ^a   Madhi, Shabir A ^b,c,d  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b Department of Science and Technology/National Research Foundation: Vaccine Preventable Diseases ^*  (United States)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

Author keywords

breast milk; Rotarix; rotavirus; transplacental antibody

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MATERNAL ANTIBODY; ROTAVIRUS VACCINE; LIVE VACCINE; NEUTRALIZING ANTIBODY; RIX4414 VACCINE; VIRUS ANTIBODY;

ARTICLE; BREAST MILK; COHORT ANALYSIS; CONTROLLED STUDY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; INFANT; LONGITUDINAL STUDY; LOWEST INCOME GROUP; NEWBORN; PLACENTAL TRANSFER; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SOUTH AFRICAN; VACCINATION; FEMALE; IMMUNOLOGY; ORAL DRUG ADMINISTRATION; ROTAVIRUS; ROTAVIRUS INFECTIONS; SERUM; SOUTH AFRICA; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; FEMALE; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INFANT; MILK, HUMAN; ROTAVIRUS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; SERUM; SOUTH AFRICA; TREATMENT OUTCOME; VACCINES, ATTENUATED;

EID: 84960114331     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ828     Document Type: Article

References (28)

1. Global networks for surveillance of rotavirus gastroenteritis, 2001-2008. Wkly Epidemiol Rec 2008; 83:421-5.
2. Statistics-South-Africa. Levels and trends of morbidity and mortality among children aged under-five years in South Africa, 2006-2010. Available at: http://www. statssa.gov.za/publications/Report-03-09-10/Report-03-09-102010.pdf. Accessed 28 September 2015.
3. Mapaseka SL, Dewar JB, van der Merwe L, et al. Prospective hospital-based surveillance to estimate rotavirus disease burden in the Gauteng and North West Province of South Africa during 2003-2005. J Infect Dis 2010; 202(suppl): S131-8.
4. Glass RI, Parashar UD. Rotavirus vaccines-balancing intussusception risks and health benefits. N Engl J Med 2014; 370:568-70.
5. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006; 354:11-22.
6. Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006; 354:23-33.
7. Armah GE, Sow SO, Breiman RF, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: A randomised, double-blind, placebo-controlled trial. Lancet 2010; 376:606-14.
8. Nelson EA, Glass RI. Rotavirus: realising the potential of a promising vaccine. Lancet 2010; 376:568-70.
9. Zaman K, Dang DA, Victor JC, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: A randomised, double-blind, placebo-controlled trial. Lancet 2010; 376: 615-23.
10. Patel MM, Glass R, Desai R, Tate JE, Parashar UD. Fulfilling the promise of rotavirus vaccines: how far have we come since licensure? Lancet Infect Dis 2012; 12:561-70.
11. Madhi SA, Cunliffe NA, Steele D, et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 2010; 362:289-98.
12. Moon SS,Wang Y, Shane AL, et al. Inhibitory effect of breast milk on infectivity of live oral rotavirus vaccines. Pediatr Infect Dis J 2010; 29:919-23.
13. Moon SS, Tate JE, Ray P, et al. Differential profiles and inhibitory effect on rotavirus vaccines of nonantibody components in breast milk from mothers in developing and developed countries. Pediatr Infect Dis J 2013; 32:863-70.
14. Novak D, Svennerholm AM. A comparison of seasonal variations in rotavirus antibodies in the breast milk of Swedish and Bangladeshi mothers. Acta Paediatr 2015; 104:247-51.
15. Patel M, Shane AL, Parashar UD, Jiang B, Gentsch JR, Glass RI. Oral rotavirus vaccines: how well will they work where they are needed most? J Infect Dis 2009; 200(suppl 1):S39-48.
16. Groome MJ, Moon SS, Velasquez D, et al. Effect of breastfeeding on immunogenicity of oral live-attenuated human rotavirus vaccine: A randomized trial in HIVuninfected infants in Soweto, South Africa. Bull World Health Organ 2014; 92:238-45.
17. Malek A, Sager R, Kuhn P, Nicolaides KH, Schneider H. Evolution of maternofetal transport of immunoglobulins during human pregnancy. Am J Reprod Immunol 1996; 36:248-55.
18. Velazquez FR, Matson DO, Guerrero ML, et al. Serum antibody as a marker of protection against natural rotavirus infection and disease. J Infect Dis 2000; 182:1602-9.
19. Becker-Dreps S, Samuel V, Velasquez Daniel, et al. Rotavirus-specific IgG antibodies from mothers' serum may inhibit infant immune responses to the pentavalent rotavirus vaccine. Pediatr Infect Dis J 2015; 34:115-6.
20. Appaiahgari MB, Glass R, Singh S, et al. Transplacental rotavirus IgG interferes with immune response to live oral rotavirus vaccine ORV-116E in Indian infants. Vaccine 2014; 32:651-6.
21. Steele AD, Reynders J, Scholtz F, et al. Comparison of 2 different regimens for reactogenicity, safety, and immunogenicity of the live attenuated oral rotavirus vaccine RIX4414 coadministered with oral polio vaccine in South African infants. J Infect Dis 2010; 202(suppl):S93-100.
22. Perkins FT, Yetts R, Gaisford W. A comparison of the responses of 100 infants to primary poliomyelitis immunization with two and with three doses of vaccine. Br Med J 1959; 1:1083-6.
23. Albrecht P, Ennis FA, Saltzman EJ, Krugman S. Persistence of maternal antibody in infants beyond 12 months: mechanism of measles vaccine failure. J Pediatr 1977; 91:715-8.
24. Gustafson CE, Higbee D, Yeckes AR, et al. Limited expression of APRIL and its receptors prior to intestinal IgA plasma cell development during human infancy. Mucosal Immunol 2014; 7:467-77.
25. Hjelt K, Grauballe PC, Nielsen OH, Schiotz PO, Krasilnikoff PA. Rotavirus antibodies in the mother and her breast-fed infant. J Pediatr Gastroenterol Nutr 1985; 4:414-20.
26. Adlhoch C, Hoehne M, Littmann M, et al. Rotavirus vaccine effectiveness and case-control study on risk factors for breakthrough infections in Germany, 2010-2011. Pediatr Infect Dis J 2013; 32:e82-9.
27. Vesikari T, Prymula R, Schuster V, et al. Efficacy and immunogenicity of live-attenuated human rotavirus vaccine in breast-fed and formula-fed European infants. Pediatr Infect Dis J 2012; 31:509-13.
28. Velasquez D, Bautista A, Esparza M, et al. Association between breastfeeding and immunogenicity of Rotarix inMexican infants [abstract W12-8]. In: Scientific program and abstracts of the 33rd Annual Meeting of the American Society for Virology (Fort Collins, CO). Toledo, OH: American Society for Virology, 2014:110.